How is Rybrevant administered?
Rybrevant is given as an intravenous (IV) infusion into your vein. Your healthcare provider will administer this medication to you, normally in a clinic-like setting. Your doctor will decide the time between doses as well as how many treatments you will receive. It may be given as a single agent or in combination with chemotherapy medicines called carboplatin and pemetrexed.
Patients usually receive this medicine until their cancer worsens or they have side effects that require the drug to be stopped. Your doctor will determine your dose (based on your weight), how many treatments you will receive, and how often you receive them.
Infusion reactions are common with Rybrevant. You will receive medicines before each dose (called "premedications") to help reduce your risk of an infusion-related reaction.
Symptoms of the infusion-related reaction may include:
- shortness of breath
- flushing
- fever
- chills
- nausea
- chest discomfort
- low blood pressure
- vomiting.
Tell your doctor right away if you have any of these side effects. Your doctor may need to temporarily stop your infusion, decrease your dose or completely stop your treatment with Rybrevant if you have serious side effects.
What is Rybrevant used for?
Rybrevant (amivantamab-vmjw) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread in the body or cannot be removed by surgery.
- Patients who receive Rybrevant have certain abnormal epidermal growth factor receptor “EGFR” genes and their NSCLC has worsened while on or after chemotherapy that contains platinum.
- Your doctor can perform a blood test to make sure you can receive Rybrevant.
- For some patients, it may be used in combination with carboplatin and pemetrexed, 2 chemotherapy medicines.
Related: Rybrevant side effects (in more detail)
Related questions
- How do Exkivity and Rybrevant compare for NSCLC?
- How does Rybrevant work?
- Is small cell or non-small cell lung cancer worse?
Can it be administered at home?
Rybrevant is not normally given at your home. You would typically receive this medicine in a healthcare facility or clinic with appropriate personnel, medicine and equipment so you can be monitored and treated for any infusion-related reactions. Your doctor will tell you when and where you will receive your infusion.
If you miss your appointment, call your healthcare provider as soon as possible to reschedule.
This is not all the information you need to know about Rybrevant (amivantamab-vmjw) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Rybrevant information here, and discuss this information and any questions you have with your doctor or other health care provider.
References
- Rybrevant (amivantamab-vmjw) prescribing information. 3/2024. Janssen Pharmaceuticals. Horsham, PA. Accessed March 5, 2024 at https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf
- Janssen Care Path. Accessed Sept. 13, 2021 at https://www.janssencarepath.com/patient/rybrevant/patient-support
- FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer. US Food and Drug Administration. May 21, 2021. Press release. Accessed Sept 13, 2021 at https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer
Read next
Is non-small cell lung cancer hereditary?
A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading
How aggressive is non-small cell lung cancer?
Non-small cell lung cancer (NSCLC) tends to spread more slowly than small cell lung cancer (SCLC). About 80% of all lung cancers are diagnosed as NSCLC. Some forms of NSCLC do grow rapidly, such as large cell undifferentiated carcinoma and large cell neuroendocrine carcinoma. Lung cancer most commonly spreads to the liver, brain, bones or adrenal glands. Continue reading
Does smoking cause non-small cell lung cancer?
Yes, smoking can cause non-small cell lung cancer (NSCLC), the most common type of lung cancer. NSCLC accounts for about 85% of all cases of lung cancer. Smoking tobacco contributes to 80% to 90% of all lung cancer deaths. Continue reading
Related medical questions
- What type of lung cancer is Vizimpro used to treat?
- What type of cancer is Tecentriq used to treat?
- How long does it take for Keytruda to work?
- Why give Taxol (Paxel) before carboplatin?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- What is Paxel called in the USA?
- How effective is Lumakras, what's the survival rate?
- How effective is Tabrecta?
- How does erlotinib work (mechanism of action)?
- What is the difference between Mvasi and Avastin?
- Are there cost-saving programs for Tecentriq?
- How long can I take Gilotrif (afatinib) for?
- Will Tabrecta cure lung cancer?
- How does Retevmo work?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- Is Tabrecta a chemotherapy drug?
- How effective is atezolizumab (Tecentriq)?
- Is Gilotrif (afatinib) a chemotherapy drug?
- What is the mechanism of action for Alecensa (alectinib)?
- Can Tarceva (erlotinib) cure lung cancer?
- How long do you take Alecensa for?
- How effective is Alecensa for ALK-positive NSCLC?
- How does pemetrexed work?
- How does Gilotrif (afatinib) work?
- Does atezolizumab (Tecentriq) cause hair loss?
- How effective is Exkivity (mobocertinib) for NSCLC?
- How long does it take for Xalkori to work?
- How to pronounce Xalkori?
- How does Alecensa work?
Drug information
Related support groups
- Rybrevant (3 questions, 3 members)
- Amivantamab (2 questions, 3 members)
- Non-Small Cell Lung Cancer (52 questions, 70 members)